LUNSUMIO
Clinical safety rating
cautionComprehensive clinical and safety monograph for LUNSUMIO (LUNSUMIO).
Comprehensive clinical and safety monograph for LUNSUMIO (LUNSUMIO).
Relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
Lunsumio (mosunetuzumab) is a bispecific CD20-directed CD3 T-cell engager that binds to CD20 on B cells and CD3 on T cells, resulting in T-cell activation and subsequent lysis of CD20-expressing B cells.
| Metabolism | Mosunetuzumab is a monoclonal antibody that is expected to be degraded into small peptides and amino acids via catabolic pathways, not metabolized by CYP450 enzymes. |
| Excretion | Excreted primarily via hepatic metabolism and biliary elimination. Less than 1% of the dose is recovered unchanged in urine. |
| Half-life | Terminal elimination half-life is approximately 22 days (range 14–34 days), supporting every 2–4 week dosing intervals. |
| Protein binding | Lunsumio exhibits high protein binding (>90%), primarily to albumin. |
| Volume of Distribution | Volume of distribution is approximately 3–4 L, suggesting limited extravascular distribution consistent with a large monoclonal antibody. |
| Bioavailability | Subcutaneous bioavailability is approximately 60–80% relative to intravenous administration. |
| Onset of Action | Subcutaneous administration: Time to first tumor response ranges from 6 to 12 weeks; maximal effect may require several months. |
| Duration of Action | Duration of action is prolonged due to long half-life; therapeutic effect persists for weeks after discontinuation. |
| Molecular Weight | 145000 |
Intravenous infusion of 1 mg/kg on Day 1 of Cycle 1, 2 mg/kg on Day 8 and Day 15 of Cycle 1, 3 mg/kg on Day 1 of Cycle 2, then 3 mg/kg every 2 weeks; premedicate with dexamethasone, acetaminophen, and diphenhydramine.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min); insufficient data for severe renal impairment (eGFR <30 mL/min) or dialysis. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A); insufficient data for moderate to severe impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy not established in pediatric patients; no recommended dose. |
| Geriatric use | No specific dose adjustment recommended; elderly patients may have higher incidence of toxicity, monitor closely. |
| 1st trimester | No adequate human data; animal studies not available. Risk cannot be ruled out. |
| 2nd trimester | No adequate human data; use only if potential benefit justifies potential risk. |
| 3rd trimester | No adequate human data; use only if potential benefit justifies potential risk. |
Clinical note
Comprehensive clinical and safety monograph for LUNSUMIO (LUNSUMIO).
| Placental transfer | Unknown; likely crosses placenta due to IgG1 antibody structure. |
| Breastfeeding | Unknown if excreted in human milk. Consider developmental and health benefits of breastfeeding alongside mother's clinical need for LUNSUMIO. |
| Lactation Rating | L4 - Possibly hazardous |
| Teratogenic Risk | First trimester: Limited data; based on mechanism (IL-6 receptor antagonist), potential for increased risk of congenital malformations cannot be excluded. Second/third trimester: Animal studies show no evidence of teratogenicity; human data insufficient. |
| Fetal Monitoring | Monitor for maternal infections (due to immunosuppression), liver function tests, neutrophil and platelet counts. In pregnancy, monitor fetal growth via ultrasound, and assess for preterm labor. Postnatal surveillance for infant infections. |
| Fertility Effects | Animal studies show no impairment of male or female fertility. Human data lacking; based on mechanism, potential for reversible effects on reproductive function due to cytokine modulation. |
■ FDA Black Box Warning
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur. Premedicate and monitor patients during infusion. Withhold or permanently discontinue based on severity.
| Serious Effects |
History of severe hypersensitivity to LUNSUMIO or its excipientsConcurrent infection requiring antimicrobial therapy (relative caution)
| Precautions | Cytokine release syndrome (CRS), Neurologic toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS), Infections, Cytopenias, Embryo-fetal toxicity |
| Food/Dietary | No specific food interactions reported. Maintain adequate hydration. No restrictions with grapefruit or other CYP inhibitors as mosunetuzumab is a monoclonal antibody, not metabolized by CYP enzymes. |
| Clinical Pearls | LUNSUMIO (mosunetuzumab) is a bispecific CD20xCD3 T-cell engager for relapsed/refractory follicular lymphoma. Administer as IV infusion with premedications (corticosteroids, antihistamines, antipyretics) to mitigate cytokine release syndrome (CRS). Step-up dosing is mandatory: cycle 1 day 1: 1 mg, day 8: 2 mg, day 15: 60 mg, then 60 mg every 3 weeks from cycle 2. Monitor for CRS (most common grade 1-2) and neurological toxicities (ICANS). Use in patients with ECOG 0-1 and adequate organ function. Do not administer with live vaccines. |
| Patient Advice | LUNSUMIO is given as an intravenous infusion over 1-4 hours. · You will receive a stepped dosing schedule to reduce side effects, with increasing doses over the first cycle. · Common side effects include fever, chills, fatigue, headache, and low blood pressure (cytokine release syndrome). Report any fever, difficulty breathing, or confusion immediately. · You may be given medications before each infusion to prevent allergic reactions and cytokine release. · Avoid live vaccines (e.g., flu nasal spray, MMR, shingles) during treatment and for at least 4 weeks after. · Inform your doctor if you have a history of infections, liver disease, or if you are pregnant or breastfeeding. |
Loading safety data…